Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748098 · ClinicalTrials.gov registry record · Phase 3
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
A Phase 3 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT00748098 is a Phase 3 study that has completed, run by XenoPort. The registered enrollment target is 136 participants.
The verdict
NCT00748098, a Phase 3 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
Interventions
- DRUG Placebo
- DRUG GSK1838262 Extended Release Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748098
The ClinicalTrials.gov registry entry for NCT00748098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00748098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748098 about?
NCT00748098 is a clinical study titled "Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance". The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
What is the current status of trial NCT00748098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00748098?
The interventions under investigation include: Placebo (DRUG), GSK1838262 Extended Release Tablets (DRUG).
Who is sponsoring clinical trial NCT00748098?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.